Role of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?

Thomas J. Lynch, Taral Patel, Luke Dreisbach, Michael McCleod, William J. Heim, Robert C. Hermann, Eugene Paschold, Nicholas O. Iannotti, Shaker Dakhil, Steven Gorton, Virginie Pautret, Martin R. Weber, Donald Woytowitz, Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099 Journal of Clinical Oncology. ,vol. 28, pp. 911- 917 ,(2010) , 10.1200/JCO.2009.21.9618

R. Labianca, M. Garassino, V. Torri, Predicting response of molecular targeted therapies: a still possible challenge? Annals of Oncology. ,vol. 19, pp. 829- 830 ,(2008) , 10.1093/ANNONC/MDN016

Shirin Khambata-Ford, Christopher T. Harbison, Lowell L. Hart, Melissa Awad, Li-An Xu, Christine E. Horak, Shaker Dakhil, Robert C. Hermann, Thomas J. Lynch, Martin R. Weber, Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 28, pp. 918- 927 ,(2010) , 10.1200/JCO.2009.25.2890

Robert Pirker, Jose R Pereira, Aleksandra Szczesna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, Valentyn Ganul, Jae-Kyung Roh, Emilio Bajetta, Kenneth O'Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, Ulrich Gatzemeier, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet. ,vol. 373, pp. 1525- 1531 ,(2009) , 10.1016/S0140-6736(09)60569-9